Evaluation of the effect of oral zinc sulfate on bilirubin level

Evaluation of the effect of oral zinc sulfate on bilirubin level in neonates with non-hemolytic unconjugated hyperbilirubinemia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120219009075N3

Enrollment

Registered

2025-12-15

Start date

2025-11-20

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Jaundice. Neonatal jaundice, unspecified

Interventions

Intervention 1: First intervention group (low dose): 5 mg in 5 cc Oral zinc sulfate syrup (Razak Company), twice daily, 5 cc each time for three days. Intervention 2: Second intervention group (High d

Eligibility

Sex/Gender

All

Age

3 Days to 10 Days

Inclusion criteria

Inclusion criteria: Term and near-term infants (gestational age greater than or equal to 35 weeks) Birth weight greater than or equal to 2500 grams Non-hemolytic unconjugated hyperbilirubinemia requiring phototherapy (total bilirubin greater than or equal to 15 mg/dL) From the beginning of three days to ten days of age Written consent from the parents (father and mother of the newborn) for entry into the study.

Exclusion criteria

Exclusion criteria: Hospitalization due to infection Major congenital anomalies (including GI anomalies) Pathologic jaundice Hypoxic ischemic encephalopathy History of taking another medication to treat jaundice Newborn with Cephal hematoma

Design outcomes

Primary

Measure	Time frame
Bilirubin levels. Timepoint: The serum bilirubin level before the intervention and daily for 3 days after the intervention. Method of measurement: Laboratory measurement of serum bilirubin levels using a peripheral blood sample by colorimetric method through Delta Darman Part kit.	—

Secondary

Measure	Time frame
Duration of phototherapy. Timepoint: From the time of hospitalization and the start of the intervention until discharge and the end of the intervention. Method of measurement: Counting phototherapy days according to a questionnaire that is completed based on record.;Length of hospitalization. Timepoint: From the time of hospitalization and the start of the intervention until discharge and the end of the intervention. Method of measurement: Counting hospitalization days according to a questionnaire that is completed based on record.	—

Measure

Time frame

Duration of phototherapy. Timepoint: From the time of hospitalization and the start of the intervention until discharge and the end of the intervention. Method of measurement: Counting phototherapy days according to a questionnaire that is completed based on record.;Length of hospitalization. Timepoint: From the time of hospitalization and the start of the intervention until discharge and the end of the intervention. Method of measurement: Counting hospitalization days according to a questionnaire that is completed based on record.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSayedeh Zohreh Jalali

Rasht University of Medical Sciences

z_jalali@gums.ac.ir+98 13 3336 9062

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026